CN1679901A - A kind of Jianganling compound preparation and preparation method - Google Patents
A kind of Jianganling compound preparation and preparation method Download PDFInfo
- Publication number
- CN1679901A CN1679901A CN 200510032804 CN200510032804A CN1679901A CN 1679901 A CN1679901 A CN 1679901A CN 200510032804 CN200510032804 CN 200510032804 CN 200510032804 A CN200510032804 A CN 200510032804A CN 1679901 A CN1679901 A CN 1679901A
- Authority
- CN
- China
- Prior art keywords
- jianganling
- extract
- extractum
- capsule
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 150000001875 compounds Chemical class 0.000 title claims description 10
- 239000007901 soft capsule Substances 0.000 claims abstract description 60
- 239000006187 pill Substances 0.000 claims abstract description 46
- 239000007919 dispersible tablet Substances 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract 7
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract 6
- 241000736075 Schisandra Species 0.000 claims abstract 4
- 240000006079 Schisandra chinensis Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 39
- 239000002775 capsule Substances 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 35
- 229920002472 Starch Polymers 0.000 claims description 28
- 239000008107 starch Substances 0.000 claims description 28
- 235000019698 starch Nutrition 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- -1 dry Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000002826 coolant Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000000314 lubricant Substances 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 16
- 235000019198 oils Nutrition 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 16
- 239000000375 suspending agent Substances 0.000 claims description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000003292 glue Substances 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 11
- 229920001249 ethyl cellulose Polymers 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 239000001856 Ethyl cellulose Substances 0.000 claims description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229960004063 propylene glycol Drugs 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 6
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229940057995 liquid paraffin Drugs 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims 5
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000002612 dispersion medium Substances 0.000 claims 4
- 239000003240 coconut oil Substances 0.000 claims 3
- 235000019864 coconut oil Nutrition 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- 235000013871 bee wax Nutrition 0.000 claims 2
- 239000012166 beeswax Substances 0.000 claims 2
- 229960003511 macrogol Drugs 0.000 claims 2
- 229910002055 micronized silica Inorganic materials 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- ONQVFVANTCVUAK-UHFFFAOYSA-N 1,3-bis(ethenyl)pyrrolidin-2-one Chemical compound C=CC1CCN(C=C)C1=O ONQVFVANTCVUAK-UHFFFAOYSA-N 0.000 claims 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 235000019489 Almond oil Nutrition 0.000 claims 1
- 235000019484 Rapeseed oil Nutrition 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims 1
- 239000008168 almond oil Substances 0.000 claims 1
- 229940034794 benzylparaben Drugs 0.000 claims 1
- 229940067596 butylparaben Drugs 0.000 claims 1
- 239000010495 camellia oil Substances 0.000 claims 1
- 239000000042 carbacrylic resin Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 235000020710 ginseng extract Nutrition 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229940070765 laurate Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 229940083037 simethicone Drugs 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract 1
- 244000132619 red sage Species 0.000 abstract 1
- 241000222336 Ganoderma Species 0.000 description 43
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 39
- 238000011282 treatment Methods 0.000 description 27
- 239000000243 solution Substances 0.000 description 17
- 230000002421 anti-septic effect Effects 0.000 description 15
- 230000001476 alcoholic effect Effects 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 238000007598 dipping method Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 229920000858 Cyclodextrin Polymers 0.000 description 10
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000007766 cera flava Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 230000006837 decompression Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000004064 recycling Methods 0.000 description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 6
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 238000002481 ethanol extraction Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 101710142246 External core antigen Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007872 degassing Methods 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 238000009413 insulation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 5
- 229960000502 poloxamer Drugs 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 4
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 235000006040 Prunus persica var persica Nutrition 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 206010019842 Hepatomegaly Diseases 0.000 description 3
- 240000005809 Prunus persica Species 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000007449 liver function test Methods 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- GJLNWLVPAHNBQN-UHFFFAOYSA-N phenyl 4-hydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OC1=CC=CC=C1 GJLNWLVPAHNBQN-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种健肝灵制剂及其制备方法。由五味子浸膏、丹参浸膏、灵芝浸膏等组份的提取物及适当的辅料制成分散片、包衣分散片、滴丸、软胶囊等剂型。本发明可提高五味子浸膏中有效成分的含量，从而提高药品的及药效。本发明剂型可不含糖，适合忌糖患者使用。The invention relates to a Jianganling preparation and a preparation method thereof. The extracts of Schisandra extract, Danshen extract, Ganoderma lucidum extract and other components are made into dispersible tablets, coated dispersible tablets, dropping pills, soft capsules and other dosage forms. The invention can increase the content of active ingredients in the schisandra extract, thereby improving the efficacy and efficacy of medicines. The dosage form of the invention may not contain sugar, and is suitable for patients who avoid sugar.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Schizandrol compound Chinese medicinal preparation and preparation method that has improved drug effect.
Technical background
JIANGANLING JIAONANG is the pure Chinese medicinal preparation that is used for acute, delay property, chronic hepatitis, has replenishing QI to invigorate the spleen, blood circulation promoting and blood stasis dispelling; Has the effect that reduces glutamate pyruvate transaminase.Record in 20 in Ministry of Public Health Chinese traditional patent formulation preparation.This medicine medicine source extensively is easy to get, and curative effect is reliable.But along with the continuous variation of environment and human adaptive variation for medicine, people have had higher requirement for the bioavailability of Chinese medicine and drug effect, drug quality.
Application number 93103427.2 discloses a kind of Schizandrol Chinese medicine preparation, and its prescription is different with theme of the present invention.
Summary of the invention
The object of the invention is to optimize the prescription medicinal substances extract process of Chinese medicine, and adds appropriate amount of auxiliary materials, and a kind of Schizandrol compound Chinese medicinal preparation and preparation method that has improved bioavailability and drug effect is provided.
The present invention takes following design: the component weight proportion of Schizandrol preparation of the present invention is:
Seed of Fructus Schisandrae Chinensis extractum 130～160g, Ganoderma extractum 20～45g, Radix Salviae Miltiorrhizae extractum 20～40g
Above-mentioned component cooperates the pharmaceutically alleged adjuvant or the substrate of the suitable kind of employing to make drop pill, soft capsule, dispersible tablet, pellet capsule respectively, as making soft capsule with disperse medium, suspending agent, antiseptic; Or make dispersible tablet with filler, disintegrating agent, wetting agent, lubricant; Or make drop pill with drop pill substrate.
Optimum ratio is: contain in 1000 soft capsules:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 50g Radix Salviae Miltiorrhizae extractum 30g
With disperse medium (80～420g), suspending agent (4～65g), (0.1～8g) makes soft capsule liquid to antiseptic; Consumption is preferred: be disperse medium 200g, suspending agent 25g, antiseptic 0.5g.
Softgel shell is made up of gelatin or Polyethylene Glycol 41.5%～68%, glycerol 1.3%, additives 0.2% and 30.5%～57.0% in water.
Contain in 1000 dispersible tablets:
It is that 50～450g, disintegrating agent are that 12～100g, lubricant are 5～15g that seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 50g Radix Salviae Miltiorrhizae extractum 30g needs filler loading.Consumption is preferred: filler loading is that 240g, disintegrating agent are that 30g, lubricant are 10g.
The drop pill of 1000 parts of doses can be 3000～20000, contains:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 50g Radix Salviae Miltiorrhizae extractum 30g drop pill substrates quantity is 80～600g.Consumption is preferred: be 240g
Medical material all uses by the record of document specifies such as Chinese Pharmacopoeia.
Seed of Fructus Schisandrae Chinensis extractum of the present invention, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum are meant through following technology and make:
Fructus Schisandrae Chinensis extrat: get seed of Fructus Schisandrae Chinensis, be crushed to 30 ~ 80 orders, can be earlier with 1～2 times of amount 95% ethanol moistening dipping, continuously filter with 7～12 times of amount 95% alcohol dipping 48 hours, filtrate is left standstill, separate oil reservoir after decompression recycling ethanol do not distinguish the flavor of to there being alcohol, promptly;
Or the improvement method for making of Fructus Schisandrae Chinensis extrat: get seed of Fructus Schisandrae Chinensis, be crushed to 30 ~ 80 orders, can continue with 7～12 times and measure 95% alcohol dipping 48 hours earlier with 1～2 times of amount 95% ethanol moistening dipping, filter, filtrate is left standstill, behind the separation oil reservoir, and weighing, what add 1/30～1/50 oil reservoir weight doubly reaches cyclodextrin, the powerful stirring makes abundant mixing 4 hours, and decompression recycling ethanol is not to there being the alcohol flavor, promptly.
This method for making gained schisandrin B content does not more add the technology that doubly reaches cyclodextrin and can significantly improve.
Ganoderma extractum: Ganoderma is got by Ganoderma extractum system, and chopping is 90% alcohol dipping 48 hours with 8 times of amount concentration, filter, decompression filtrate recycling ethanol gets ethanol extraction, medicinal residues decoct with water twice, and each 2 hours, collecting decoction, filter, filtrate is concentrated into thick paste, merges with above-mentioned ethanol extraction, add appropriate amount of starch, mixing, drying, promptly.
Radix Salviae Miltiorrhizae extractum: Radix Salviae Miltiorrhizae is got by Radix Salviae Miltiorrhizae extractum system, is ground into 20～60 purpose coarse powder, decocts with water 3 times, and each 6～12 times of amounts, each 2 hours, collecting decoction filtered, and filtrate is concentrated in right amount, drying, promptly.
Merge above-mentioned three kinds of extracts, be preparation drop pill, dispersible tablet, soft capsule,, the used medicinal substances extract of micropill.
Prepare soft capsule by following steps:
I) modulation capsule liquid: get one or more of seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, adding disperse medium, antiseptic, suspending agent, emulsifying agent etc., stir, grind homogenizing, promptly get soft capsule liquid;
Ii) get gelatin, water, in heating in water bath dissolving down, mix homogeneously adds glycerol, antiseptic, additives, stirs, and after the vacuumize degassing, insulation is left standstill, and makes capsule material glue;
Iii) suppress or drip and make soft capsule: capsule liquid is encapsulated in the capsule material glue with soft capsule system of dripping or press; Promptly get the Schizandrol soft capsule.
The disperse medium of making soft capsule is: olive oil or other crude vegetals, or triglyceride oils, or oleic acid sorbitol ester, or olein: propylene glycol is 90: 10 mixture by weight, or Oleum Cocois C8/C10 monoglyceride or dibasic acid esters, or Oleum Cocois C8/C10 propylene glycol ester, or Oleum Cocois triglyceride, or the acetylizad monoglyceride of purification, or olein, or glyceryl linoleate, or the Polyethylene Glycol glyceryl laurate ester, or in the purification Oleum helianthi monoglyceride one or more, or the best peach kernel oil that uses: 1: 1 mixture of Oleum Sesami weight ratio;
The suspending agent of soft capsule is: can increase the solid matter of disperse medium viscosity, and as Cera Flava, aluminum monostearate, ethyl cellulose, carbomer etc., or the best Cera Flava that uses: 1.5: 3.5 mixture of ethyl cellulose weight ratio;
The antiseptic of soft capsule is: one or more in glycerol, propylene glycol, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl p-hydroxybenzoate, the P-hydroxybenzoic acid phenyl ester.
Prepare dispersible tablet by following steps:
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, add filler and part disintegrating agent mix homogeneously, granulate with the wetting agent moistening, drying, granulate adds remaining disintegrating agent and lubricant, mix homogeneously tabletting, promptly get the Schizandrol dispersible tablet, or wrap again according to making coated dispersing tablet.
Its The disintegrating agents of dispersible tablets is: crospolyvinylpyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, one or more of cross-linked carboxymethyl cellulose sodium etc., or the best crospolyvinylpyrrolidone that uses: 5: 1 mixture of cross-linked carboxymethyl cellulose sodium weight ratio;
Binding agent in the dispersible tablet is: the alcoholic solution of 40% ethanol～95% alcoholic solution or starch slurry or polyvinylpyrrolidone, or best 85% alcoholic solution that uses;
Filler is in the dispersible tablet: starch, or lactose or microcrystalline Cellulose, or one or more of precoking starch, mannitol etc., or the best starch that uses: lactose: 1: 2: 1 mixture of mannitol weight ratio;
Lubricant in the dispersible tablet is a magnesium stearate, or micropowder silica gel, or one or more of Pulvis Talci etc., or bestly uses micropowder silica gel.
Prepare drop pill by following steps:
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, add in the hot drop pill substrate of melting, mix homogeneously splashes into molding in the coolant, removes coolant, promptly gets the Schizandrol drop pill.
Described drop pill substrate is: Polyethylene Glycol is meant one or both the combination of Macrogol 4000 or polyethylene glycol 6000, and the best is a Macrogol 4000: the mixture of polyethylene glycol 6000 (3: 11), consumption are 80～600g; Condensing agent in its drop pill preparation is one of dimethicone, liquid paraffin, Oleum Camelliae, vegetable oil or two or more.
The preparation pellet capsule:
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, with doubly reach mix homogeneously such as cyclodextrin, precoking starch, take a morsel earlier to place and play female ball in the full-automatic coating pelletizing machine, select the appropriate female ball of particle diameter, continue to add medicated powder, reach 16～20 orders until particle diameter, gained micropill drying, or the coating after drying, promptly;
Described weight proportion is seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum: 100 parts, doubly reach 5 parts of cyclodextrin, and 10 parts of ethyl celluloses, 8 parts of precoking starch, 10 parts of microcrystalline Cellulose, wetting agent are 85% alcoholic solution of 6% polyvinylpyrrolidone.
Effect of the present invention:
Be objective evaluation Schizandrol treatment viral hepatitis clinical efficacy and safety, take random packet, the test method of contrast, Schizandrol soft capsule group, drop pill group, each 120 examples (male 95 example of dispersible tablet group, woman's 25 examples), JIANGANLING JIAONANG group 118 examples (male 97 examples, women 21 examples).
1 clinical data
Allly meet the full infectious disease of Chinese medical and the parasite chronic hepatitis B diagnostic criteria of can national meeting formulating for the third time in May nineteen ninety-five, age is in 18-60 year, male or female, and meet following condition: (1) HBsAg and HbeAg or anti--HBe are more than positive lasting half a year.(2) preceding 3 months of treatment or above Serum ALT continue or are undesired repeatedly, (3) serum bilirubin＜30 μ mol/L.(4) Serological testing does not have acute first type, third type and hepatitis E.(5) no decompensated cirrhosis.(6) clinical and lab testing does not have autoimmune hepatitis and alcoholic liver injury.(7) half a year not used antiviral drugs and immunoregulation medicine.
Therapeutic Method
The treatment group is totally 243 examples, takes Schizandrol soft capsule, drop pill, dispersible tablet respectively, soft capsule every day 3 times, each each 2; Or 20 of drop pill, 2 of dispersible tablets (dose and former capsule are consistent), continuing for 8 weeks is 1 course of treatment.Matched group is totally 72 examples, takes JIANGANLING JIAONANG, and every day 3 times, each 3, continuing for 38 weeks is 1 course of treatment.Matched group case alternative condition is identical with the treatment group.More than remove during two groups of treatments and use general vitamin B, outside C the is aid digestion class medicine, all not reuse antiviral drugs, immunoregulation medicine and have the hepatoprotective of reducing enzyme and treating jaundice.Difference not statistically significant (P＞0.05) is analysed in aspects such as two groups of patient ages, sex, the course of disease, symptom credit by statistics.
1.3 observation item and index
Per two weekly check ALT before the treatment, after the treatment beginning are till A5T, total bilirubin, A/G finish to treatment; Survey inspection HBsAg before the treatment, in the treatment, when treatment finishes respectively, HBeAg, anti--HBc (enzyme is exempted from method), HBV-DNA (PCR) method; The sings and symptoms of the relevant hepatitis of per two week records; The untoward reaction of regularly filling in summary sheet and writing down medicine,
1.4 curative effect determinate standard
Produce effects: subjective symptoms disappears, and the chronic hepatitis sign alleviates, and liver function test ALT, bilirubin recover normal, among the HBV-M HBeAg or (with) HBV-DNA turns out cloudy.
Effectively: subjective symptoms disappears or takes a turn for the better, and the chronic hepatitis sign is stable, and liver function test ALT, bilirubin recover normal, HBeAg or (with) HBV-DNA do not turn out cloudy.
Invalid: the subjective symptoms no change, the chronic hepatitis sign is constant, and liver function test is still unusual, HBeAg, HBV-DNA does not all turn out cloudy:
1.5 statistical method X
2Check and definite probabilistic method, inspection level.α＝0.05。
2 results
2.1 two groups of patient's clinical symptoms Signs are improved situation analysis and are seen Table 1:
| Group | Poor appetite | Feel sick | Weak | Liver is painful | Abdominal distention | Hepatomegaly | Splenomegaly | Liver palm | ??ALT | ??SB | |
| The treatment group | Unusually | ??103 | ??72 | ??103 | ??70 | ??82 | ??46 | ??12 | ??20 | ??120 | ??29 |
| Recover | ??101 | ??72 | ??85 | ??58 | ??70 | ??38 | ??6 | ??0 | ??98 | ??24 | |
| Matched group | Unusually | ??97 | ??69 | ??99 | ??59 | ??79 | ??45 | ??11 | ??21 | ??118 | ??27 |
| Recover | ??86 | ??68 | ??81 | ??35 | ??31 | ??22 | ??5 | ??0 | ??71 | ??23 | |
| ??X 2Value | ??7.261 | ??0.000 | ??0.017 | ??16.204 | ??36.616 | ??1.515 | ??0.000 | ??0.00 | ??13.356 | ??0.00 | |
| The P value | ??0.007 | ??0.489 | ??0.896 | ??0.000 | ??0.000 | ??0.001 | ??1.000 | ??0.50 | ??0.00 | ??1.00 |
As aspect the elimination such as nauseating, weak, two groups of difference are little in common clinical symptoms and Signs, but the treatment group is better than matched group aspect the eliminations such as, abdominal distention painful at sodium error, liver, hepatomegaly, and both differences all have statistical significance (P＜0.05); Also be better than matched group (P＜0.05) in treatment group aspect the ALT normalization rate.
The situation analysis 2.2 two groups of patient's hepatitis b virus markers are turned out cloudy.
Table 2: two groups of patient's hepatitis b virus markers situation analysis (example) of turning out cloudy
| Group | ????????????HBeAg | Anti-HBC | ????????HBV-DNA | ||||||
| Positive | Turn out cloudy | Negative conversion rate | Positive | Turn out cloudy | Negative conversion rate | Positive | Turn out cloudy | Negative conversion rate | |
| The treatment group | ??96 | ??36 | ??37.5 | ??115 | ??0 | ??0 | ??101 | ????39 | ??38.6 |
| Matched group | ??95 | ??17 | ??17.9 | ??116 | ??0 | ??0 | ??103 | ????19 | ??18.4 |
| ??X 2Value | ????????????9.154 | ??????????0.000 | ????????????10.193 | ||||||
| The P value | ????????????0.002 | ???????????1.000 | ????????????0.001 | ||||||
2.3 two groups of patient treatment interpretations of result see Table 3.
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate |
| Treatment group 1 | ??120 | ??44(36.7) | ????67(55.8) | ????9(7.5) | ??92.5 |
| Treatment group 2 | ??60 | ??21(35.0) | ????29(48.3) | ????4(6.7) | ??83.3 |
| Treatment group 3 | ??63 | ??22(34.9) | ????31(49.2) | ????5(7.9) | ??84.1 |
| Matched group | ??118 | ??26(22.0) | ????49(41.5) | ????43(36.4) | ??63.5 |
Conclusion:
Chronic hepatitis B sickness rate height accounts for hepatitis B about 20%, and the course of disease is long, is difficult for radical cure, causes liver cirrhosis easily, and with primary hepatoma certain relation is arranged, and does not still have special effect medicine therapeutic at present both at home and abroad.The active drug of seeking the treatment chronic hepatitis B is the current very important problem of the world of medicine.Carry out clinical controlling by using Schizandrol, obtain satisfied effect, two groups there is no tangible untoward reaction in therapeutic process.
This paper result shows that Schizandrol treatment chronic hepatitis B curative effect in Clinical Application is satisfied, the effective percentage height, and short treating period has no adverse reaction, and is a relatively effective and safe drug.Excellent JIANGANLING JIAONANG is organized in treatment aspect the eliminations such as the Schizandrol soft capsule aches poor appetite, liver, abdominal distention, hepatomegaly, and both differences all have statistical significance (P＜0.05); Also be better than matched group (P＜0.05) in treatment group aspect the ALT normalization rate.
Advantage of the present invention is:
Drop pill: drop pill is the modern Chinese medicine novel form, belongs to solid dispersion system, and it is big to have specific surface area, and stripping is fast, the characteristics that bioavailability is high.And manufacturing cost is lower.Drops mostly is chemicals and uses, and the development of Chinese medicine dripping pills needs to test the choose reasonable substrate and make flow process by a large amount of.
Soft capsule: the soft capsule introduction also claims the flexible glue pill, and it is not have a kind of preparation that forms in sealings such as the non-water-soluble liquid of dissolution or suspension and the capsule shells with oils or to the gelatin thing.Soft capsule is the tablet that continues, and a kind of novel form that grows up after the injection, its shell are to form with the gelatin compacting, the aqueous medicinal liquid of bag in the softgel shell.The invention discloses the prescription and the method for making of Schizandrol soft capsule liquid and capsule material, the gained soft capsule quality is stable.
Dispersible tablet: be a kind of solidified liquid form of administration, disintegrate fully in 3 minutes at normal temperatures, the effective ingredient stripping is rapid.But solid state is taken, but also liquid condition is taken, and makes things convenient for the patient.The development of dispersible tablets of Chinese medicine need overcome and extract the difficult point that the extractum moisture absorption influences disintegrate, and the present invention is by the screening adjuvant, thereby it is stable to reach end product quality, and disintegrate is characteristics rapidly.
The forming technique of the present micropill of pellet capsule has multiple as rolls into ball method, method of extruding and kneading to pellets centrifugal fluidized granulation method etc., the invention discloses Schizandrol is made microsphere and its preparation and adjuvant, one-tenth ball method cost of the present invention is low, mustn't special installation gained micropill outward appearance bright and clean, the granularity unanimity; Good fluidity, size evenly are easy to fill.
Original capsule extracts active ingredients in preparation process is insufficient, and the schisandrin B yield is lower in the preparation, causes the waste of herb resource.Former dosage form is rotten for preventing the extract moisture absorption, has increased more starch based adjuvant, the large size capsule of every dress 0.5g, and the patient takes inconvenience, the usually therapy discontinued because taking inconvenience, or selection other drug.Innovation dosage form of the present invention, it is convenient that the patient is taken, and the medical material utilization rate is higher, and bioavailability of medicament, drug effect also have raising comparatively significantly, thereby the patient can be followed the doctor's advice, and finish the treatment of the corresponding course of treatment.
The specific embodiment:
Experimental example 1: the preparation of Schizandrol extract
Fructus Schisandrae Chinensis extrat:
Get seed of Fructus Schisandrae Chinensis, be crushed to 80 orders, can be earlier with 1.5 times of amount 95% ethanol moistening dippings, continuously filter with 8 times of amount 95% alcohol dipping 48 hours, filtrate is left standstill, separate oil reservoir after decompression recycling ethanol do not distinguish the flavor of to there being alcohol, promptly;
Ganoderma extractum:
Ganoderma is got by Ganoderma extractum system, and chopping is 90% alcohol dipping 48 hours with 8 times of amount concentration, filter, decompression filtrate recycling ethanol gets ethanol extraction, medicinal residues decoct with water twice, and each 2 hours, collecting decoction, filter, filtrate is concentrated into thick paste, merges with above-mentioned ethanol extraction, add appropriate amount of starch, mixing, drying, promptly.
Radix Salviae Miltiorrhizae extractum:
Radix Salviae Miltiorrhizae is got by Radix Salviae Miltiorrhizae extractum system, is ground into 40 purpose coarse powder, decoct with water 3 times, and each 10 times of amounts, each 2 hours, collecting decoction filtered, and filtrate is concentrated in right amount, drying, promptly.
Merge above-mentioned three kinds of extracts, be preparation drop pill, dispersible tablet, soft capsule,, the used medicinal substances extract of micropill.
Experimental example 2: improved the preparation of the Schizandrol extract of Fructus Schisandrae Chinensis extracting method:
The improvement method for making of Fructus Schisandrae Chinensis extrat:
Get seed of Fructus Schisandrae Chinensis, be crushed to 60 orders, can continue with 10 times and measure 95% alcohol dipping 48 hours earlier with 2 times of amount 95% ethanol moistening dippings, filter, filtrate is left standstill, behind the separation oil reservoir, and weighing, what add 140 oil reservoir weight doubly reaches cyclodextrin, the powerful stirring makes abundant mixing 4 hours, and decompression recycling ethanol is not to there being the alcohol flavor, promptly.
Compare with the preparation that does not add cyclodextrin inclusion compound among the embodiment 1, schisandrin B content on average exceeds about 21%.
Ganoderma extractum:
Ganoderma is got by Ganoderma extractum system, and chopping is 90% alcohol dipping 48 hours with 8 times of amount concentration, filter, decompression filtrate recycling ethanol gets ethanol extraction, medicinal residues decoct with water twice, and each 2 hours, collecting decoction, filter, filtrate is concentrated into thick paste, merges with above-mentioned ethanol extraction, add appropriate amount of starch, mixing, drying, promptly.
Radix Salviae Miltiorrhizae extractum:
Radix Salviae Miltiorrhizae is got by Radix Salviae Miltiorrhizae extractum system, is ground into 20～60 purpose coarse powder, decoct with water 3 times, and each 6～12 times of amounts, each 2 hours, collecting decoction filtered, and filtrate is concentrated in right amount, drying, promptly.
Merge above-mentioned three kinds of extracts, be preparation drop pill, dispersible tablet, soft capsule,, the used medicinal substances extract of micropill.
Embodiment 3: the preparation of Schizandrol drop pill:
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g, Ganoderma extractum 40g, Radix Salviae Miltiorrhizae extractum 30g
Macrogol 4000 600g
Make 5000
Get the 220g medicinal substances extract, in the drop pill substrate Polyethylene Glycol 9300 that 80 ℃ of heat of adding are melted, mix homogeneously splashes into molding in the coolant, removes coolant, promptly gets the Schizandrol drop pill
Coolant: 2 ℃ of liquid paraffin are an amount of
Embodiment 4: the preparation of Schizandrol drop pill:
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 40g Radix Salviae Miltiorrhizae extractum 30g
Macrogol 4000: polyethylene glycol 6000 (7.5: 2.5) 120g
Poloxamer 20g
Make 10000
The preparation drop pill: medicinal substances extract is crushed to 120 orders, taking polyethylene glycol 4000: 85 ℃ of heating and melting of polyethylene glycol 6000 (7.5: 2.5) water-bath, the fine powder that adds medicinal substances extract, and poloxamer, mix homogeneously, splash into while hot in the two first class silicone oil liquid coolants, drip and make drop pill, ball heavily is controlled to be 0.045～0.055, removes liquid coolant, coating promptly gets the commodity drop pill.
The mixture that keeps medicinal substances extract and substrate when dripping system is in 82 ℃, 90 centimetres of cooling column effective column lengths, and 5 ℃ of liquid coolants are dripped 55 on fast every part of clock, dropper mouth external diameter 2.5mm, internal diameter 2.0mm, then dripping the drop pill of making does not have the tail of taking off, and outward appearance is bright and clean shaped.
Coating solution is: polyvinylpyrrolidone 20g
Hydroxypropyl methylcellulose 5g
95% alcoholic solution 198m1
Pulvis Talci 6g
Magnesium stearate 2g
Titanium dioxide 6g
Polyethylene glycol 6000 2g
Pigment 3g
Embodiment 5: the preparation of Schizandrol drop pill:
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g, Ganoderma extractum 40g, Radix Salviae Miltiorrhizae extractum 30g
Macrogol 4000: polyethylene glycol 6000 (3: 11) 240g
Poloxamer 20g
Coolant: dimethicone is an amount of
Make 20000
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, be crushed to 100 orders or thinner, add in the hot drop pill substrate of melting, mix homogeneously splashes into molding in the coolant, removes coolant, promptly gets the Schizandrol drop pill.
Embodiment 6: the preparation of Schizandrol drop pill:
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g, Ganoderma extractum 40g, Radix Salviae Miltiorrhizae extractum 30g
Polyethylene Glycol 9300 60g
Poloxamer 20g
Make 2000
Coolant: dimethicone is an amount of
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, add in the hot drop pill substrate of melting, mix homogeneously splashes into molding in the coolant, removes coolant, promptly gets the Schizandrol drop pill.
Coolant: dimethicone is an amount of
Substrate in its drop pill is molecular weight by cured one or more of 2000～12000 Polyethylene Glycol, polyoxyethylene monostearate, sodium stearate or glycerin gelatine, poloxamer, stearic acid, glyceryl monostearate, worm.
Embodiment 7: the Schizandrol preparation of soft capsule
Seed of Fructus Schisandrae Chinensis extractum 450g Ganoderma extractum 120g Radix Salviae Miltiorrhizae extractum 90g
Cera Flava 65g;
Olive oil 420g
Propylene glycol 8g
Soybean lecithin 20
Make 1000
I) modulation capsule liquid: get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, adding disperse medium, antiseptic, suspending agent, emulsifying agent etc., stir, grind homogenizing, promptly get soft capsule liquid;
Ii) get gelatin, water, in heating in water bath dissolving down, mix homogeneously adds glycerol, antiseptic, additives, stirs, and after the vacuumize degassing, insulation is left standstill, and makes capsule material glue;
Iii) suppress or drip and make soft capsule: capsule liquid is encapsulated in the capsule material glue with soft capsule system of dripping or press; Control capsule grain is heavy, makes and makes 1000, promptly.
Cera Flava is a suspending agent, and the emulsifying agent soybean lecithin is an emulsifying agent in its soft capsule.
Olive oil is that the oil phase disperse medium also can be: the triglyceride oils of crude vegetal (as: soybean oil, Oleum Arachidis hypogaeae semen) or long-chain and medium-chain saturation in various degree, as: oleic acid sorbitol ester, olein: propylene glycol (90: 10), Oleum Cocois C8/C10 monoglyceride or dibasic acid esters, Oleum Cocois C8/C10 propylene glycol ester, Oleum Cocois triglyceride, the acetylizad monoglyceride of purification (Myvacet oil), olein, glyceryl linoleate, Polyethylene Glycol glyceryl laurate ester, purification Oleum helianthi monoglyceride.
Embodiment 8: the Schizandrol preparation of soft capsule
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 40g Radix Salviae Miltiorrhizae extractum 30g
Peach kernel oil 160g
Oleum Sesami 80g:
Cera Flava: ethyl cellulose weight ratio 1.5: 3.5 25
Ethylparaben 0.5g
Make 1000
I) modulation capsule liquid: get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, adding disperse medium, antiseptic, suspending agent, emulsifying agent etc., stir, grind homogenizing, promptly get soft capsule liquid;
Ii) get gelatin, water, in heating in water bath dissolving down, mix homogeneously adds glycerol, antiseptic, additives, stirs, and after the vacuumize degassing, insulation is left standstill, and makes capsule material glue;
Iii) make or drip and make soft capsule: capsule liquid is encapsulated in the capsule material glue with soft capsule system of dripping or press; Promptly get the Schizandrol soft capsule.
The suspending agent of soft capsule is: can increase the solid matter of disperse medium viscosity, as Cera Flava, aluminum monostearate, ethyl cellulose, carbomer etc. one or more.
The antiseptic of soft capsule is: one or more in glycerol, propylene glycol, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl p-hydroxybenzoate, the P-hydroxybenzoic acid phenyl ester.
Embodiment 9: the Schizandrol preparation of soft capsule
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 40g Radix Salviae Miltiorrhizae extractum 30g
Peach kernel oil: 1: 1 80g of Oleum Sesami:
Cera Flava: 1.5: 3.5 4g of ethyl cellulose weight ratio
Ethylparaben 0.1g
Make 1000
I) modulation capsule liquid: get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, adding disperse medium, antiseptic, suspending agent, emulsifying agent etc., stir, grind homogenizing, promptly get soft capsule liquid;
Ii) get gelatin, water, in heating in water bath dissolving down, mix homogeneously adds glycerol, antiseptic, additives, stirs, and after the vacuumize degassing, insulation is left standstill, and makes capsule material glue;
Iii) suppress or drip and make soft capsule: capsule liquid is encapsulated in the capsule material glue with soft capsule system of dripping or press; Promptly get the Schizandrol soft capsule.
Embodiment 10: the Schizandrol preparation of soft capsule
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 40g Radix Salviae Miltiorrhizae extractum 30g
Peach kernel oil: 1: 1 200g of Oleum Sesami:
Cera Flava: ethyl cellulose weight ratio 1.5: 3.5 25
Ethylparaben 0.5g
I) modulation capsule liquid: get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, adding disperse medium, antiseptic, suspending agent, emulsifying agent etc., stir, grind homogenizing, promptly get soft capsule liquid;
Ii) get gelatin, water, in heating in water bath dissolving down, mix homogeneously adds glycerol, antiseptic, additives, stirs, and after the vacuumize degassing, insulation is left standstill, and makes capsule material glue;
Iii) suppress or drip and make soft capsule: capsule liquid is encapsulated in the capsule material glue with soft capsule system of dripping or press; Promptly get the Schizandrol soft capsule.
Softgel shell is made up of gelatin or Polyethylene Glycol 58%, glycerol 1.3%, additives 0.2% and water 40.5%.
Embodiment 11: the preparation of Schizandrol dispersible tablet
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 40g Radix Salviae Miltiorrhizae extractum 30g
Filler: pregelatinized Starch 30g and lactose 20g form;
Disintegrating agent: crospolyvinylpyrrolidone 8g;
Lubricant: magnesium stearate 5g;
Correctives: xylitol 30g;
Make 1000 Schizandrol dispersible tablets.
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, with pregelatinized Starch lactose and crospolyvinylpyrrolidone mix homogeneously, dilute alcohol solution (5 parts of polyvinylpyrrolidones: moistening system soft material 80% ethanol 100ml) with the content polyvinylpyrrolidone, granulate, drying, granulate adds disintegrating agent low-substituted hydroxypropyl cellulose disintegrating agent and lubricant micropowder silica gel and xylitol 30g tabletting, the bag film-coat, promptly.
The coating solution prescription can for:
Polyvinylpyrrolidone 24g
Crospolyvinylpyrrolidone 2g
Hydroxypropyl methylcellulose 4g
95% alcoholic solution 210ml
Pulvis Talci 5g
Magnesium stearate 2g
Titanium dioxide 6g
Polyethylene glycol 6000 3g
Pigment 3g
Embodiment 12: the preparation of Schizandrol dispersible tablet
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 40g Radix Salviae Miltiorrhizae extractum 30g
Pregelatinized Starch 210g
Lactose 240g;
Carboxymethyl starch sodium 16g
Low-substituted hydroxypropyl cellulose 48g;
Lubricant: micropowder silica gel 15g;
Correctives: xylitol 3g;
Make 1000 Schizandrol dispersible tablets.
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, with pregelatinized Starch lactose and carboxymethyl starch sodium 16g mix homogeneously, dilute alcohol solution (5 parts of polyvinylpyrrolidones: moistening system soft material 80% ethanol 100ml) with the content polyvinylpyrrolidone, granulate, dry, granulate adds disintegrating agent low-substituted hydroxypropyl cellulose disintegrating agent and lubricant micropowder silica gel and xylitol 3g tabletting, promptly gets the Schizandrol dispersible tablet.
Embodiment 13: the preparation of Schizandrol dispersible tablet
The component weight proportion:
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 40g Radix Salviae Miltiorrhizae extractum 30g
Starch 60g
Lactose 120g
Manna 60g
Crospolyvinylpyrrolidone 25g
Cross-linked carboxymethyl cellulose sodium 5g
Lubricant: micropowder silica gel 15g;
Make 1000 Schizandrol dispersible tablets.
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum, add filler and part disintegrating agent mix homogeneously, granulate with wetting agent 85% alcoholic solution moistening, dry, granulate, add remaining disintegrating agent and lubricant, mix homogeneously tabletting, promptly get the Schizandrol dispersible tablet, or wrap again according to making coated dispersing tablet.
Its The disintegrating agents of dispersible tablets is: crospolyvinylpyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, one or more of cross-linked carboxymethyl cellulose sodium etc., or the best crospolyvinylpyrrolidone that uses: 5: 1 mixture of cross-linked carboxymethyl cellulose sodium weight ratio;
Binding agent in the dispersible tablet is: the alcoholic solution of 40% ethanol～95% alcoholic solution or starch slurry or polyvinylpyrrolidone, or best 85% alcoholic solution that uses;
Filler is in the dispersible tablet: starch, or lactose or microcrystalline Cellulose, or one or more of precoking starch, mannitol etc., or the best starch that uses: lactose: 1: 2: 1 mixture of mannitol weight ratio;
Lubricant in the dispersible tablet is a magnesium stearate, or micropowder silica gel, or one or more of Pulvis Talci etc., or bestly uses micropowder silica gel.
Embodiment 14: the preparation of Schizandrol pellet capsule
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 50g Radix Salviae Miltiorrhizae extractum 30g
Doubly reach cyclodextrin 11g
Ethyl cellulose 22g
Precoking starch 16g
Microcrystalline Cellulose 22g
85% alcoholic solution 60ml of wetting agent (or claiming adhesive) 6% polyvinylpyrrolidone
Get seed of Fructus Schisandrae Chinensis extractum, Ganoderma extractum, Radix Salviae Miltiorrhizae extractum and be crushed to 100 orders or thinner, with doubly reach mix homogeneously such as cyclodextrin, precoking starch, take a morsel earlier to place and play female ball in the full-automatic coating pelletizing machine, select the appropriate female ball of particle diameter, continue to add medicated powder, reach 16～20 orders until particle diameter, with gained micropill drying, capsular 1000 of packing;
Embodiment 15: the preparation of Schizandrol pellet capsule
Seed of Fructus Schisandrae Chinensis extractum 150g Ganoderma extractum 50g Radix Salviae Miltiorrhizae extractum 30g
Doubly reach cyclodextrin 15g
Ethyl cellulose 24g
Precoking starch 10g
Microcrystalline Cellulose 15g
85% alcoholic solution 80ml of wetting agent (or claiming adhesive) 11% polyvinylpyrrolidone
The coated formula of micropill is:
Polyvinylpyrrolidone 20g
Hydroxypropyl methylcellulose 6g
95% alcoholic solution 198ml
Pulvis Talci 5g
Magnesium stearate 2g
Titanium dioxide 4g
Polyethylene glycol 6000 2g
Pigment 1g
With Fructus Schisandrae Chinensis by embodiment 2 become the seed of Fructus Schisandrae Chinensis extractum, be crushed to 100 orders or thinner by said ratio and Ganoderma extractum, Radix Salviae Miltiorrhizae extractum; with mix homogeneously such as second class cellulose element, precoking starch; take a morsel earlier to place and play female ball in the full-automatic coating pelletizing machine; select the appropriate female ball of particle diameter; continue to add medicated powder, reach 16～20 orders until particle diameter, gained micropill drying; coating, drying are distributed into capsular 1000 of every 0.3g.
Compare with the preparation that does not add cyclodextrin inclusion compound in the Fructus Schisandrae Chinensis extraction, schisandrin B content on average exceeds 21%.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100328040A CN1320881C (en) | 2005-01-21 | 2005-01-21 | A drop pill for treating acute and chronic hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100328040A CN1320881C (en) | 2005-01-21 | 2005-01-21 | A drop pill for treating acute and chronic hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679901A true CN1679901A (en) | 2005-10-12 |
| CN1320881C CN1320881C (en) | 2007-06-13 |
Family
ID=35066907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100328040A Expired - Fee Related CN1320881C (en) | 2005-01-21 | 2005-01-21 | A drop pill for treating acute and chronic hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1320881C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977888B (en) * | 2005-12-05 | 2012-03-07 | 山东轩竹医药科技有限公司 | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza |
| CN103494897A (en) * | 2013-09-30 | 2014-01-08 | 秦福玉 | Traditional Chinese medicine for treating chronic hepatitis |
| CN113577178A (en) * | 2021-09-07 | 2021-11-02 | 香河县人民医院 | Traditional Chinese medicine composition and medical application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173443A (en) * | 2014-08-16 | 2014-12-03 | 黑龙江江恒医药科技有限公司 | Liver invigorating tablet and preparation method thereof |
-
2005
- 2005-01-21 CN CNB2005100328040A patent/CN1320881C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977888B (en) * | 2005-12-05 | 2012-03-07 | 山东轩竹医药科技有限公司 | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza |
| CN103494897A (en) * | 2013-09-30 | 2014-01-08 | 秦福玉 | Traditional Chinese medicine for treating chronic hepatitis |
| CN113577178A (en) * | 2021-09-07 | 2021-11-02 | 香河县人民医院 | Traditional Chinese medicine composition and medical application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1320881C (en) | 2007-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1686267A (en) | Chinese medicinal preparation for channel warming and blood nourishing and its preparation method | |
| CN1239183C (en) | A Chinese medicinal composition and its preparation method | |
| CN1686352A (en) | Medicine for treating high lipemia and its production method | |
| CN1679901A (en) | A kind of Jianganling compound preparation and preparation method | |
| CN1745797A (en) | Medicine for treating menstrual irregularities and menalgia | |
| CN1319560C (en) | Chinese medicine compound rheumatism preparation for improving bioavailability and medicine effect and preparing method | |
| CN101040999A (en) | Medicine compound for treating snoring and the preparing method and the quality control method | |
| CN1268377C (en) | Preparation for improving bioavailability and medicine effect for treating gynecopathy and preparing method | |
| CN1316997C (en) | Preparation for free flowing ginew and bone and its preparation method | |
| CN1698709A (en) | A kind of compound Scutellaria baicalensis preparation | |
| CN1679807A (en) | Heat-clearing and stranguria-relieving Chinese medicine preparation and production thereof | |
| CN1679802A (en) | Preparation of strengthening waist and health-caring kidney and its making method | |
| CN1698716A (en) | Gynecological Chinese medicinal preparation for stopping pain and expelling blood stasis | |
| CN1723964A (en) | A medicine for treating cough and asthma and chronic bronchitis | |
| CN1602945A (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1814110A (en) | Medicine for treating gynecophathy | |
| CN1253170C (en) | Chinese medicine preparation for treating hepatitis and its preparing and detecting method | |
| CN1634293A (en) | Xianlinggubao new preparation and its preparation method and use | |
| CN1698714A (en) | 'Rukuaixiao' preparation for treating mammary disease and its preparation process | |
| CN1623599A (en) | Xiaoyao soft capsule and its preparation technology | |
| CN1660248A (en) | A kind of Dan'e Fukang preparation and its preparation method | |
| CN1682885A (en) | Hemostatic preparation for gynecology department | |
| CN1772122A (en) | Indian stringbush prepn with antiphlogistic and detoxicating functions | |
| CN1698715A (en) | Heat-clearing abortion-preventing Chinese medicine and its preparation method | |
| CN1626211A (en) | Astragalus-leech preparation of lowering blood sugar for treating diabetes and syndrome and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: GUANGDONG LUOFUSHAN SINOPHARM Co.,Ltd. Assignor: Ye Yaoliang Contract record no.: 2010440001149 Denomination of invention: Compound preparation of Jianganling for liver and its making method Granted publication date: 20070613 License type: Exclusive License Open date: 20051012 Record date: 20100813 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190214 Address after: 516133 Bianling Pai Industrial Zone of Guangshan Highway, Changning Town, Boluo County, Huizhou City, Guangdong Province (Luofushan Pharmaceutical City) Patentee after: GUANGDONG LUOFUSHAN SINOPHARM Co.,Ltd. Address before: 516100 No. 36 Qiaodong three road, Luoyang Town, Boluo County, Huizhou, Guangdong Patentee before: Ye Yaoliang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070613 |